Glenmede Investment Management’s Cytokinetics CYTK Stock Holding History

Glenmede Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$604K	Buy	+10,990	New	+$453K	﹤0.01%	857

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Glenmede Investment Management's CYTK Position: Q3 2025 in Review

Glenmede Investment Management opened a new position in Cytokinetics (CYTK) in Q3 2025: 10,990 shares worth $604K. The stake represents ﹤0.01% of the portfolio and ranks #857 among its holdings.

380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

Glenmede Investment Management held 10,990 shares of Cytokinetics worth $604K as of Q3 2025.
Cytokinetics was a new Glenmede Investment Management position in Q3 2025.
Cytokinetics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #857 holding.
380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.